WINNIEDEL ONCOLOGY and CLINEXEL Enter Strategic Partnership to Advance Global Oncology Research
WINNIEDEL ONCOLOGY, the world’s first and only global Study Start-Up (SSU) early-phase oncology CRO, is delighted to announce our strategic partnership with CLINEXEL, full-service Clinical Research Organization renowned for comprehensive clinical trial expertise across Phases I to IV. This partnership strategically combines WINNIEDEL’s robust global oncology site network, spanning the USA, Latin America, and Europe, with CLINEXEL’s extensive international clinical research capabilities.
“This partnership exemplifies our unwavering dedication to transforming cancer care through strategic global collaboration," says Tandy Tipps, CEO of WINNIEDEL ONCOLOGY. "Together, WINNIEDEL and CLINEXEL will accelerate the delivery of innovative therapies to patients in need, significantly improving clinical outcomes and efficiency.”
WINNIEDEL ONCOLOGY is dedicated to efficiently aligning oncology trials with optimal sites, significantly reducing Study Start-Up (SSU) and First Patient In (FPI) timelines, thereby accelerating patient access to potentially life-saving cancer treatments. The company's Global Oncology Site Universe (GOSU) and its extensive network of Key Opinion Leaders (KOLs) distinctly position the company as an industry leader in early-phase oncology clinical trials.
Partnering with CLINEXEL significantly enhances WINNIEDEL ONCOLOGY's collective capability to support biotech companies from study inception through submission, delivering patient-centric, efficient, and globally integrated clinical trial solutions. CLINEXEL’s comprehensive end-to-end services— including Global Clinical Development, Regulatory Affairs, Medical Writing, Clinical Data Management, and Pharmacovigilance—perfectly align with its mission to streamline and optimize oncology trial execution worldwide.
CLINEXEL is a full member of AICROS, an association of 9 CRO members covering clinical operations in the USA, Europe, India, Africa, China, Israel, Australia and New Zealand. This large coverage with local clinical operations expertise is immensely helpful for companies planning Global Clinical Trials.
Dr. Deepa, CEO of CLINEXEL, highlighted the mutual benefits of the partnership: "This collaboration is complementary to CLINEXEL’s capabilities in the USA and crucial for strengthening our global presence in oncology research.”
WINNIEDEL ONCOLOGY and CLINEXEL share a unified vision to put cancer patients first, reduce clinical trial challenges, and deliver innovative treatments faster. Together, we offer unparalleled expertise, global reach, and a personalized approach, empowering biotech and pharma companies to achieve groundbreaking outcomes in oncology.